TY - JOUR
T1 - Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma
AU - Yano, S.
AU - Mori, T.
AU - Kanda, Y.
AU - Kato, J.
AU - Nakaseko, C.
AU - Fujisawa, S.
AU - Tomita, N.
AU - Sakai, R.
AU - Shono, K.
AU - Saitoh, T.
AU - Aotsuka, N.
AU - Kobayashi, N.
AU - Saito, T.
AU - Takahashi, S.
AU - Kanamori, H.
AU - Okamoto, S.
N1 - Publisher Copyright:
© 2015 Macmillan Publishers Limited.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients - 11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.
AB - Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients - 11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.
UR - http://www.scopus.com/inward/record.url?scp=84943422621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943422621&partnerID=8YFLogxK
U2 - 10.1038/bmt.2015.158
DO - 10.1038/bmt.2015.158
M3 - Article
C2 - 26168068
AN - SCOPUS:84943422621
VL - 50
SP - 1299
EP - 1305
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 10
ER -